Physician profile
Abbe Schickner
NPI 1629537436
$878.69
in general payments reported to CMS, 2019-2025
18 companies · $308 in 2025
The $308 reported for 2025 was more than what a typical Obstetrics & Gynecology provider received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $22.68 · 2023: $125 · 2024: $423 · 2025: $308.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $856.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $856.01 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Organon LLC | $126.80 | 2023-2025 | Nexplanon, Nuvaring |
| Coopersurgical, INC. | $98.24 | 2023-2025 | Paragard T 380a, Summit Doppler |
| Astellas Pharma US INC | $94.75 | 2024-2025 | Veozah |
| Becton, Dickinson and Company | $75.48 | 2024 | Bd Max System, Bd Max Instrument |
| Sumitomo Pharma America, INC. | $67.11 | 2024-2025 | Myfembree, Gemtesa |
| Abbvie INC. | $52.03 | 2022-2024 | |
| Shield Therapeutics INC | $50.28 | 2023-2024 | Accrufer |
| Bayer Healthcare Pharmaceuticals INC. | $46.68 | 2023-2024 | |
| Pfizer INC. | $40.06 | 2024-2025 | |
| Millicent US INC | $37.54 | 2023-2025 | Intrarosa, Femring, Femlyv |
| Mayne Pharma Commercial LLC | $35.44 | 2024-2025 | |
| Sage Therapeutics, LLC | $31.52 | 2023-2025 | Zurzuvae |
| Roche Diagnostics Corporation | $24.06 | 2024 | Cobas Liat Analyzer |
| Ethicon US, LLC | $23.80 | 2024 | Vistaseal, Ethicon, Prolene |
| Dexcom, INC. | $22.95 | 2025 | Dexcom G6 Transmitter |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $19.41 | 2024 | V-Loc 180 |
| Hologic Sales and Service, LLC | $18.27 | 2024 | Novasure, Acessa Provu System, Myosure Tissue Removal Device |
| Supernus Pharmaceuticals, INC. | $14.27 | 2025 | Qelbree |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Abbe Schickner listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.